Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

Background Long-acting injectable formulations of antipsychotics are treatment alternatives to oral agents. Aims To assess the efficacy of aripiprazole once-monthly compared with oral aripiprazole for maintenance treatment of schizophrenia. Method A 38-week, double-blind, active-controlled, non-inferiority study; randomisation (2:2:1) to aripiprazole once-monthly 400 mg, oral aripiprazole (10–30 mg/day) or aripiprazole once-monthly 50mg (a dose below the therapeutic threshold for assay sensitivity). (Trial registration: clinicaltrials.gov, NCT00706654.) Results A total of 1118 patients were screened, and 662 responders to oral aripiprazole were randomised. Kaplan–Meier estimated impending relapse rates at week 26 were 7.12% for aripiprazole once-monthly 400mg and 7.76% for oral aripiprazole. This difference (−0.64%, 95% CI −5.26 to 3.99) excluded the predefined non-inferiority margin of 11.5%. Treatments were superior to aripiprazole once-monthly 50mg (21.80%, P⩽0.001). Conclusions Aripiprazole once-monthly 400mg was non-inferior to oral aripiprazole, and the reduction in Kaplan–Meier estimated impending relapse rate at week 26 was statistically significant v. aripiprazole once-monthly 50 mg.

• Publication year

  2014

• Venue

  British Journal of Psychiatry

• Publication date

  2014-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.bp.113.134213PMID 24925984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Columbia-Suicide Severity Rating Scale

  2016cited by this paper
• Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

  2014cited by this paper
• Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.

  2013cited by this paper
• Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

  2013cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

  2013cited by this paper
• Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• Aripiprazole: a review of its use in the management of schizophrenia in adults.

  2012cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

  2011cited by this paper
• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

  2009cited by this paper
• Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.

  2008cited by this paper
• The attitude of patients towards antipsychotic depot treatment

  2007cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

  2003cited by this paper
• Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.

  2003cited by this paper
• Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain.

  2003cited by this paper
• Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

  2003cited by this paper
• Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

  2002cited by this paper
• A Rating Scale for Drug-Induced Akathisia

  1989cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper

• Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs.

  2025influential citation
• Eficacia comparativa del aripiprazol de liberación prolongada: Estudio de administración mensual versus bimestral en pacientes con Trastorno mental grave

  2025cites this paper
• A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole

  2025cites this paper
• Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States.

  2025cites this paper
• Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

  2025cites this paper
• Treatment effectiveness and preference in patients with schizophrenia switched from oral standard of care atypical antipsychotics to aripiprazole once-monthly: a brief report over a six-month period

  2025cites this paper
• Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases

  2025influential citation
• Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study

  2025cites this paper
• Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report.

  2025cites this paper
• Systematic review of long-acting injectable antipsychotic medications approved from 2008 to october 2024 and agents in phase 3.

  2024cites this paper
• Factors Affecting Continuation of Aripiprazole Long-acting Injection in the Real World

  2024influential citation
• All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis

  2024cites this paper
• Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study

  2024cites this paper
• An analysis of multiple comparisons is conducted to account for correlations among various investigated variables across four categories of antipsychotics

  2024cites this paper
• Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders

  2023cites this paper
• Impact of long-acting injectable aripiprazole on the concomitant medication and antipsychotic polypharmacy: a retrospective, observational study of 127 patients with psychosis

  2023cites this paper
• BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

  2023cites this paper
• A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

  2023cites this paper
• Blood pressure and heart rate in aripiprazole once – monthly and paliperidone 1 and 3-month long-acting preparations

  2023cites this paper
• Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)

  2023cites this paper
• Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis

  2023cites this paper
• Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy

  2023cites this paper
• Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole

  2023cites this paper
• Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

  2022cites this paper
• Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia

  2022cites this paper
• Antipsychotic dose reduction compared to dose continuation for people with schizophrenia

  2022cites this paper
• Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.

  2022cites this paper
• Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies

  2022cites this paper
• Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis

  2022cites this paper
• Study of the acute and repeated dose 28-day oral toxicity in mice treated with PT-31, a molecule with a potential antipsychotic profile

  2022cites this paper
• The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review

  2022cites this paper
• Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study

  2022influential citation
• Depot aripiprazole: subverted trials and authorisation of a best-selling drug

  2021cites this paper
• An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection

  2021cites this paper
• Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection

  2021cites this paper
• Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

  2021cites this paper
• Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.

  2021cites this paper
• Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

  2021cites this paper
• Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study

  2021cites this paper
• Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.

  2021cites this paper
• Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.

  2021cites this paper
• Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study

  2021influential citation
• Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?

  2021cites this paper
• Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)

  2021cites this paper
• The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole

  2021cites this paper
• A safety evaluation of aripiprazole in the treatment of schizophrenia

  2020cites this paper
• Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong

  2020cites this paper
• Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review.

  2020cites this paper
• Maintenance treatment with antipsychotic drugs for schizophrenia.

  2020cites this paper
• Safety and effectiveness of long-acting injectable Aripiprazole in daily practice: A naturalistic retrospective study

  2020influential citation
• Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence

  2020cites this paper
• Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study

  2020influential citation
• Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study

  2020cites this paper
• The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index

  2020cites this paper
• The effectiveness of long-term aripiprazole injections to a patient with paranoid schizophrenia: a case report

  2020influential citation
• Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report.

  2020cites this paper
• Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología

  2020cites this paper
• Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials.

  2020cites this paper
• Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia

  2020cites this paper
• Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs

  2019cites this paper
• Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

  2019cites this paper
• Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review

  2019cites this paper
• Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

  2019cites this paper
• The Long-Acting Injectable Antipsychotics in Clinical Practice

  2019cites this paper
• Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies

  2019cites this paper
• The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies

  2019cites this paper
• NDT_A_198241 1659..1669

  2019cites this paper
• Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations

  2019cites this paper
• Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

  2018cites this paper
• Treatment Continuation of 3 Second-Generation Antipsychotic Long-Acting Injections, and Oral Paliperidone in Patients With Schizophrenia for 2 Years.

  2018cites this paper
• PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT.

  2018cites this paper
• Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

  2018cites this paper
• Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis

  2018cites this paper
• The effects of different periods of co‐administration of oral and long‐acting injectable aripiprazole: A propensity score analysis

  2018cites this paper
• The role of aripiprazole in the treatment of schizophrenia and mood disorders

  2018cites this paper
• Tratamiento con aripiprazol en la práctica clínica: consenso de un panel de expertos

  2018cites this paper
• Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update

  2018cites this paper
• TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians*

  2018cites this paper
• Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

  2018influential citation
• Efficacy and Tolerability of Aripiprazole Intramuscular as Maintenance Treatment in Patients with Paranoid Schizophrenia

  2017cites this paper
• Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies.

  2017cites this paper
• Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.

  2017cites this paper
• Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration

  2017influential citation
• Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.

  2017cites this paper
• Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method.

  2017influential citation
• Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies.

  2017cites this paper
• Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.

  2017cites this paper
• Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

  2017cites this paper
• Aripiprazole long-acting injection – a mirror image study of its effects on hospitalisation at one year

  2017cites this paper
• Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly

  2017cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Adjunctive Memantine in Clozapine-Treated Refractory Schizophrenia: An Open-Label One-Year Extension Study

  2017cites this paper
• Antipsychotic combinations for schizophrenia.

  2017cites this paper
• Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries.

  2017cites this paper
• Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).

  2016cites this paper
• [Evaluating the efficacy of long acting injectable antipsychotics through clinical trials].

  2016cites this paper
• Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

  2016cites this paper